- Home
- ZVSA vs ALLR Comparison
ZVSA vs ALLR Comparison
Compare ZVSA & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVSA
- ALLR
- Stock Information
- Founded
- ZVSA 2014
- ALLR 2004
- Country
- ZVSA United States
- ALLR United States
- Employees
- ZVSA N/A
- ALLR N/A
- Industry
- ZVSA Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- ZVSA Health Care
- ALLR Health Care
- Exchange
- ZVSA Nasdaq
- ALLR Nasdaq
- Market Cap
- ZVSA 2.3M
- ALLR 2.3M
- IPO Year
- ZVSA N/A
- ALLR N/A
- Fundamental
- Price
- ZVSA $1.08
- ALLR $1.32
- Analyst Decision
- ZVSA Strong Buy
- ALLR
- Analyst Count
- ZVSA 1
- ALLR 0
- Target Price
- ZVSA $240.00
- ALLR N/A
- AVG Volume (30 Days)
- ZVSA 3.6M
- ALLR 658.4K
- Earning Date
- ZVSA 11-14-2024
- ALLR 11-14-2024
- Dividend Yield
- ZVSA N/A
- ALLR N/A
- EPS Growth
- ZVSA N/A
- ALLR N/A
- EPS
- ZVSA N/A
- ALLR N/A
- Revenue
- ZVSA N/A
- ALLR N/A
- Revenue This Year
- ZVSA N/A
- ALLR N/A
- Revenue Next Year
- ZVSA N/A
- ALLR N/A
- P/E Ratio
- ZVSA N/A
- ALLR N/A
- Revenue Growth
- ZVSA N/A
- ALLR N/A
- 52 Week Low
- ZVSA $1.05
- ALLR $1.26
- 52 Week High
- ZVSA $42.35
- ALLR $666.00
- Technical
- Relative Strength Index (RSI)
- ZVSA 27.91
- ALLR 32.39
- Support Level
- ZVSA $1.34
- ALLR $1.32
- Resistance Level
- ZVSA $1.89
- ALLR $1.53
- Average True Range (ATR)
- ZVSA 0.25
- ALLR 0.12
- MACD
- ZVSA -0.08
- ALLR 0.05
- Stochastic Oscillator
- ZVSA 1.29
- ALLR 14.63
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.